Literature DB >> 30728278

Feasibility Assessment of Using the Complete Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item Library.

Daniel Shepshelovich1,2,3, Kate McDonald1, Anna Spreafico1,3, Albiruni R A Razak1,3, Philippe L Bedard1,3, Lillian L Siu1,3, Lori Minasian4, Aaron R Hansen5,3.   

Abstract

The patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) complements capture of symptomatic adverse events (AEs) by clinicians. Previous trials have typically used a limited subset of relevant symptomatic AEs to reduce patient burden. We aimed to determine the feasibility of administering all 80 AEs included in the PRO-CTCAE library by approaching consecutive patients enrolled in a large academic phase I program at three points in time. Here, we report a preplanned analysis after enrolling the first 20 patients. All items were answered on 51 of 56 potential visits (adherence 91%). Three (5%) additional PRO-CTCAE assessments were partially completed, and two (4%) were missed because of conflicting appointments. No patient withdrew consent or chose not to complete the assessments once enrolled on study. Future trials of experimental drugs that incorporate the PRO-CTCAE should consider using this unselected approach to identify adverse events more completely. © AlphaMed Press 2019.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30728278      PMCID: PMC6459233          DOI: 10.1634/theoncologist.2018-0332

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  13 in total

1.  Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Authors:  Amylou C Dueck; Tito R Mendoza; Sandra A Mitchell; Bryce B Reeve; Kathleen M Castro; Lauren J Rogak; Thomas M Atkinson; Antonia V Bennett; Andrea M Denicoff; Ann M O'Mara; Yuelin Li; Steven B Clauser; Donna M Bryant; James D Bearden; Theresa A Gillis; Jay K Harness; Robert D Siegel; Diane B Paul; Charles S Cleeland; Deborah Schrag; Jeff A Sloan; Amy P Abernethy; Deborah W Bruner; Lori M Minasian; Ethan Basch
Journal:  JAMA Oncol       Date:  2015-11       Impact factor: 31.777

Review 2.  Patient-Reported Outcomes in Cancer Clinical Trials: Measuring Symptomatic Adverse Events With the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Authors:  Paul G Kluetz; Diana T Chingos; Ethan M Basch; Sandra A Mitchell
Journal:  Am Soc Clin Oncol Educ Book       Date:  2016

3.  Feasibility of Patient Reporting of Symptomatic Adverse Events via the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in a Chemoradiotherapy Cooperative Group Multicenter Clinical Trial.

Authors:  Ethan Basch; Stephanie L Pugh; Amylou C Dueck; Sandra A Mitchell; Lawrence Berk; Shannon Fogh; Lauren J Rogak; Marcha Gatewood; Bryce B Reeve; Tito R Mendoza; Ann M O'Mara; Andrea M Denicoff; Lori M Minasian; Antonia V Bennett; Ann Setser; Deborah Schrag; Kevin Roof; Joan K Moore; Thomas Gergel; Kevin Stephans; Andreas Rimner; Albert DeNittis; Deborah Watkins Bruner
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-02-10       Impact factor: 7.038

Review 4.  Incorporating the patient experience into regulatory decision making in the USA, Europe, and Canada.

Authors:  Paul G Kluetz; Daniel J O'Connor; Katherine Soltys
Journal:  Lancet Oncol       Date:  2018-05       Impact factor: 41.316

5.  Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes.

Authors:  Ethan Basch; Xiaoyu Jia; Glenn Heller; Allison Barz; Laura Sit; Michael Fruscione; Mark Appawu; Alexia Iasonos; Thomas Atkinson; Shari Goldfarb; Ann Culkin; Mark G Kris; Deborah Schrag
Journal:  J Natl Cancer Inst       Date:  2009-11-17       Impact factor: 13.506

6.  Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial.

Authors:  Ethan Basch; Allison M Deal; Mark G Kris; Howard I Scher; Clifford A Hudis; Paul Sabbatini; Lauren Rogak; Antonia V Bennett; Amylou C Dueck; Thomas M Atkinson; Joanne F Chou; Dorothy Dulko; Laura Sit; Allison Barz; Paul Novotny; Michael Fruscione; Jeff A Sloan; Deborah Schrag
Journal:  J Clin Oncol       Date:  2015-12-07       Impact factor: 44.544

7.  Feasibility and clinical impact of sharing patient-reported symptom toxicities and performance status with clinical investigators during a phase 2 cancer treatment trial.

Authors:  Ethan Basch; William A Wood; Deborah Schrag; Camelia S Sima; Mary Shaw; Lauren J Rogak; Mark G Kris; Marwan Shouery; Antonia Bennett; Thomas Atkinson; M Catherine Pietanza
Journal:  Clin Trials       Date:  2015-11-04       Impact factor: 2.486

8.  Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials.

Authors:  Ethan Basch; Amylou C Dueck; Lauren J Rogak; Lori M Minasian; William Kevin Kelly; Ann M O'Mara; Andrea M Denicoff; Drew Seisler; Pamela J Atherton; Electra Paskett; Lisa Carey; Maura Dickler; Rebecca S Heist; Andrew Himelstein; Hope S Rugo; William M Sikov; Mark A Socinski; Alan P Venook; Douglas J Weckstein; Diana E Lake; David D Biggs; Rachel A Freedman; Charles Kuzma; Jeffrey J Kirshner; Deborah Schrag
Journal:  JAMA Oncol       Date:  2017-08-01       Impact factor: 31.777

9.  Mode equivalence and acceptability of tablet computer-, interactive voice response system-, and paper-based administration of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Authors:  Antonia V Bennett; Amylou C Dueck; Sandra A Mitchell; Tito R Mendoza; Bryce B Reeve; Thomas M Atkinson; Kathleen M Castro; Andrea Denicoff; Lauren J Rogak; Jay K Harness; James D Bearden; Donna Bryant; Robert D Siegel; Deborah Schrag; Ethan Basch
Journal:  Health Qual Life Outcomes       Date:  2016-02-19       Impact factor: 3.186

10.  Patient-reported tolerability of adverse events in phase 1 trials.

Authors:  Clémence Henon; Delphine Lissa; Xavier Paoletti; Constance Thibault; Christophe Le Tourneau; Emilie Lanoy; Antoine Hollebecque; Christophe Massard; Jean-Charles Soria; Sophie Postel-Vinay
Journal:  ESMO Open       Date:  2017-06-23
View more
  10 in total

1.  Recommended scoring approach for the pediatric patient-reported outcomes version of the Common Terminology Criteria for Adverse Events.

Authors:  Pamela S Hinds; Laura C Pinheiro; Molly McFatrich; Mia Waldron; Justin N Baker; Catriona Mowbray; Scott H Maurer; Yao Cheng; Bryce B Reeve; Jichuan Wang
Journal:  Pediatr Blood Cancer       Date:  2021-12-06       Impact factor: 3.838

Review 2.  Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies.

Authors:  Gita Thanarajasingam; Lori M Minasian; Vishal Bhatnagar; Franco Cavalli; R Angelo De Claro; Amylou C Dueck; Tarec C El-Galaly; Neil Everest; Jan Geissler; Christian Gisselbrecht; Nicole Gormley; John Gribben; Mary Horowitz; S Percy Ivy; Caron A Jacobson; Armand Keating; Paul G Kluetz; Yok Lam Kwong; Richard F Little; Matthew J Matasar; Maria-Victoria Mateos; Kristen McCullough; Robert S Miller; Mohamad Mohty; Philippe Moreau; Lindsay M Morton; Sumimasa Nagai; Abhilasha Nair; Loretta Nastoupil; Kaye Robertson; Surbhi Sidana; Karin E Smedby; Pieter Sonneveld; Kyriaki Tzogani; Flora E van Leeuwen; Galina Velikova; Diego Villa; John R Wingard; John F Seymour; Thomas M Habermann
Journal:  Lancet Haematol       Date:  2022-05       Impact factor: 30.153

3.  Tomato Juice Consumption Could Improve Breast Skin Adverse Effects of Radiotherapy in Breast Cancer Patients.

Authors:  Yasuyo Fukushi; Yasushi Mariya; Kyogo Yamada; Kazue Yoshida; Asami Sasa; Hitoshi Saito; Ayumi Hirai; Shigenori Suzuki; Koichi Aizawa; Hiroyuki Suganuma; Chieko Itaki
Journal:  In Vivo       Date:  2020 Sep-Oct       Impact factor: 2.155

4.  Patient-Reported Outcomes for Tolerability Assessment in Phase I Cancer Clinical Trials.

Authors:  Ethan Basch; Christina Yap
Journal:  J Natl Cancer Inst       Date:  2021-08-02       Impact factor: 13.506

5.  Online monitoring of patient self-reported adverse events in early phase clinical trials: Views from patients, clinicians, and trial staff.

Authors:  Fiona Kennedy; Leanne Shearsmith; Michael Ayres; Oana C Lindner; Lewis Marston; Alison Pass; Sarah Danson; Galina Velikova
Journal:  Clin Trials       Date:  2020-11-24       Impact factor: 2.486

6.  Trends in patient-reported outcome use in early phase dose-finding oncology trials - an analysis of ClinicalTrials.gov.

Authors:  Julia Lai-Kwon; Zhulin Yin; Anna Minchom; Christina Yap
Journal:  Cancer Med       Date:  2021-10-22       Impact factor: 4.452

Review 7.  Key considerations to reduce or address respondent burden in patient-reported outcome (PRO) data collection.

Authors:  Olalekan Lee Aiyegbusi; Jessica Roydhouse; Samantha Cruz Rivera; Paul Kamudoni; Peter Schache; Roger Wilson; Richard Stephens; Melanie Calvert
Journal:  Nat Commun       Date:  2022-10-12       Impact factor: 17.694

8.  Underreporting of Symptomatic Adverse Events in Phase I Clinical Trials.

Authors:  Zachary W Veitch; Daniel Shepshelovich; Christina Gallagher; Lisa Wang; Albiruni R Abdul Razak; Anna Spreafico; Philippe L Bedard; Lillian L Siu; Lori Minasian; Aaron R Hansen
Journal:  J Natl Cancer Inst       Date:  2021-08-02       Impact factor: 13.506

9.  Development of patient-reported outcomes item set to evaluate acute treatment toxicity to pelvic online magnetic resonance-guided radiotherapy.

Authors:  P K Møller; H Pappot; U Bernchou; T Schytte; K B Dieperink; Pia Krause Møller
Journal:  J Patient Rep Outcomes       Date:  2021-06-23

10.  Efficacy and safety of endovascular brachytherapy combined with transarterial chemoembolization for the treatment of hepatocellular carcinoma patients with type III or IV portal vein tumor thrombosis.

Authors:  Ling Li; Niangmei Cheng; Xinhui Huang; Xiadi Weng; Yubin Jiao; Jingfeng Liu; Wuhua Guo
Journal:  World J Surg Oncol       Date:  2022-02-02       Impact factor: 2.754

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.